Zobrazeno 1 - 10
of 173
pro vyhledávání: '"Zafer, Gulbas"'
Autor:
Yishan Ye, Myriam Labopin, Jia Chen, Zafer Gulbas, Xi Zhang, Yener Koc, Didier Blaise, Fabio Ciceri, Emmanuelle Polge, Mohamed Houhou, Lin Li, Yi Luo, Depei Wu, He Huang, Mohamad Mohty, Norbert-Claude Gorin
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-5 (2023)
Abstract There are situations where non-first-degree (NFD) related donors have to be considered as alternatives to first-degree (FD) related donors for haploidentical hematopoietic cell transplantation (HAPLO). However, the efficacy of these NFD rela
Externí odkaz:
https://doaj.org/article/a16dc88c432440bd8fe28a486a085b92
Autor:
Beyhan Durak Aras, Sevgi Isik, Hava Uskudar Teke, Abdulvahap Aslan, Filiz Yavasoglu, Zafer Gulbas, Fatih Demirkan, Hulya Ozen, Oguz Cilingir, Nur Sena Inci, Gulcin Gunden, Tuba Bulduk, Ebru Erzurumluoglu Gokalp, Sinem Kocagil, Sevilhan Artan, Olga Meltem Akay
Publikováno v:
Molecular Cytogenetics, Vol 14, Iss 1, Pp 1-7 (2021)
Abstract Background Deletion of 13q14 [del(13q)] is the most common cytogenetic change (50%) in chronic lymphoblastic leukemia (CLL), and it is a good prognostic factor if it is detected as a sole aberration by FISH. However, it is observed the clini
Externí odkaz:
https://doaj.org/article/ce7069f8615f4634a0687320dd93d0ec
Publikováno v:
Transfusion Clinique et Biologique. 30:82-86
SARs were examined occurred within 1 hour after initiating HSC product infusions in all HSCT done in Turkey's Anadolu Medical Center Hospital accredited for HSCTs between 2013 and 2015, targeting 315 patients.SARs were carefully evaluated in this stu
Autor:
Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Maria Fogliatto, Alejandro Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Özcan, Guilherme Fleury Perini, Herve Ghesquieres, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand
Publikováno v:
Blood Journal.
Previous analyses of the phase 2 KEYNOTE-170 (NCT02576990) study demonstrated effective antitumor activity and acceptable safety of pembrolizumab 200 mg given every 3 weeks for up to 35 cycles (~2 years) in patients with relapsed/refractory (R/R) pri
Autor:
Elif Birtas Atesoglu, Zafer Gulbas, Ant Uzay, Muhit Ozcan, Fahir Ozkalemkas, Mehmet Sinan Dal, Hakan Kalyon, Olga Meltem Akay, Burak Deveci, Huseyin Bekoz, Omur Gokmen Sevindik, Tayfur Toptas, Fergun Yilmaz, Derya Koyun, Nihan Alkis, Inci Alacacioglu, Mehmet Sonmez, Irfan Yavasoglu, Anil Tombak, Ozgur Mehtap, Fatih Kurnaz, Orhan Kemal Yuce, Volkan Karakus, Mehmet Turgut, Derya Deniz Kurekci, Mesut Ayer, Muzaffer Keklik, Deram Buyuktas, Murat Ozbalak, Burhan Ferhanoglu
Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2497f4e81be510fd6626ab724fb52159
https://hdl.handle.net/11424/289907
https://hdl.handle.net/11424/289907
Autor:
Yishan Ye, Myriam Labopin, Jia Chen, Zafer Gulbas, Xi Zhang, Yener Koc, Didier Blaise, Fabio Ciceri, Emmanuelle Polge, Houhou Mohamad, Lin Li, Yi Luo, Depei Wu, He Huang, Mohamad Mohty, Norbert Claude Gorin
Publikováno v:
Blood. 140:10603-10605
Autor:
Annalisa Paviglianiti, Alberto Mussetti, Maud Ngoya, Ariane Boumendil, Zafer Gulbas, Fabio Ciceri, Francesca Bonifazi, Domenico Russo, Nathalie Fegueux, Friedrich Stölzel, Claude-Eric Bulabois, Gerard Socie, Edouard Forcade, Carlos Solano, Hervé Finel, Stephen Robinson, Silvia Montoto, Bertram Glass
Publikováno v:
Blood. 140:7645-7646
Autor:
Anna Waszczuk-Gajda, Irene Donnini, Ron Ram, Katia Codeluppi, Tulay Ozcelik, Diana Averbuch, Şahika Zeynep Akı, Dan Engelhard, Galina Klyasova, Simone Cesaro, Malgorzata Mikulska, Cristina Tecchio, Anastasia Pouli, Rodrigo Martino, Catherina Lueck, Rafael de la Cámara, Zafer Gulbas, Peter J. Shaw, Thomas Pabst, Lidia Gil, Simona Iacobelli, Batia Avni, Jennifer Hoek, Emmanuelle Nicolas-Virelizier, Gloria Tridello, Aida Botelho de Sousa, Tracey A. O'Brien, Alexandra Jungova, Hamdi Akan, Tsila Zuckerman, Elisabetta Calore, Per Ljungman, Lucrecia Yaňez San Segundo, Claudio Annaloro, Katia Perruccio, Montserrat Batlle, Jan Styczyński
Publikováno v:
JOURNAL OF INFECTION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau)
Journal of Infection
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau)
Journal of Infection
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Objectives: We present here data on Gram-negative rods bacteremia (GNRB) rates, risk factors and associated mortality. Methods: Data on GNRB episodes were prospectively collected in 65 allo-/67 auto-HSCT centers in 24 countries (Europe, Asia, Austral
Autor:
Burhan Ferhanoglu, Zafer Gulbas, Ant Uzay, Muhit Özcan, Fahir Ozkalemkas, Mehmet Sinan Dal, Hakan Kalyon, Olga Meltem Akay, Burak Deveci, Huseyin Bekoz, Omur Gokmen Sevindik, Tayfur Toptas, Asu Fergun Yilmaz, Derya Koyun, Nihan Alkis, Elif Birtas Atesoglu
INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response (CR) following firstline treatment wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6c58326f2cbd99b6d8617bb5c240e79
https://hdl.handle.net/20.500.12511/10604
https://hdl.handle.net/20.500.12511/10604
Autor:
Ali Bazarbachi, Yener Koc, Concepcion Herrera, Luca de Rosa, Mutlu Arat, Rocco Pastano, Hakan Ozdogu, Mohamad Mohty, Paolo Bernasconi, Didier Blaise, Célestine Simand, Luca Castagna, J. L. Diez-Martin, Myriam Labopin, Antonin Vitek, Rovira Montserrat, Giuseppe Marotta, Gérard Socié, Eolia Brissot, Fabio Ciceri, Emanuele Angelucci, Andrew M. McDonald, Zafer Gulbas, Guiseppe Visani, Pietro Pioltelli, Arnon Nagler, Wolf Rösler, Sebastian Giebel, Yves Chalandon, Paola Carluccio, Boris V. Afanasyev, Massimo Martino
Publikováno v:
Biology of Blood and Marrow Transplantation, Vol. 26, No 5 (2020) pp. 936-942
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, Elsevier, 2020, 26 (5), pp.936-942. ⟨10.1016/j.bbmt.2020.01.003⟩
Biology of Blood and Marrow Transplantation, 2020, 26 (5), pp.936-942. ⟨10.1016/j.bbmt.2020.01.003⟩
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, Elsevier, 2020, 26 (5), pp.936-942. ⟨10.1016/j.bbmt.2020.01.003⟩
Biology of Blood and Marrow Transplantation, 2020, 26 (5), pp.936-942. ⟨10.1016/j.bbmt.2020.01.003⟩
Allogeneic hematopoietic cell transplantation (HCT) is recommended in high-risk patients with T cell acute lymphoblastic leukemia (T-ALL). For patients without an HLA-identical donor, haploidentical (haplo-) HCT is becoming the leading source of stem